抗CCP抗体与类风湿关节炎临床表现的相关性(3)
 |
| 第1页 |
参见附件(2454KB，3页)。
[7] Mediwake R, Isenberg DA, Schellekens GA, et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis [J]. Ann Rheum Dis, 2001,60(1):67-68.
[8] Vencovsky J, Machácek S, SedováL, et al. Autoantibodies can be prognosticmarkers of an erosive disease in early rheumatoid arthritis [J]. Ann Rheum Dis,2003,62(5):427-430.
[9] Visser H. How to diagnose rheumatoid arthritis early: a prediction model for persistent erosive arthritis [J]. Arthritis Rheum,2002,46(2):357-365.
[10] Meyer O, Labarre C, Dougados M, et al. Anti-citrullinated protein/ptide antibody assays in early rheumatoid arthritis for predicting Wveradio-graphic damage [J]. Ann Rheum Dis,2003,62(2):120-126.
[11] Ronnelid J, Wic MC, Lampa J, et al. Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 years follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression [J]. Ann Rheum Dis,2005,64(12):1744-1749.
[12] Kastbom A, Strandberg G, Lindroos A, et al. Anti-CCP antibody predicts the disease course during 3 years in earlyrheumatoid arthritis (the Swedish TIRA project) [J]. Ann Rheum Dis,2004,63(9):1085-1089.
[13] Forslind K, Ahhnen M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of anti-bodies to citrullinated peptides (anti-CCP) [J]. Ann Rheum Dis,2004,63(9):1090-1095.
(收稿日期：2011-06-27)
[基金项目] 河北省科技厅科技攻关计划(编号：10276105D-7)。
[作者简介] 沈桂英(1970-)，女，医学硕士，主治医师，从事内科临床工作。
您现在查看是摘要介绍页，详见PDF附件(2454KB，3页)。